ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 217 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 1.66 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $2,725,000 | +68.5% | 101,500 | +1.5% | 0.33% | +30.7% |
| Q4 2018 | $1,617,000 | +7.4% | 100,000 | +37.9% | 0.25% | +78.9% |
| Q3 2018 | $1,505,000 | +97.0% | 72,500 | +45.0% | 0.14% | +89.3% |
| Q2 2018 | $764,000 | -32.0% | 50,000 | 0.0% | 0.08% | -35.3% |
| Q1 2018 | $1,124,000 | -25.4% | 50,000 | 0.0% | 0.12% | -40.5% |
| Q4 2017 | $1,506,000 | -20.1% | 50,000 | 0.0% | 0.20% | -21.4% |
| Q3 2017 | $1,884,000 | +32.5% | 50,000 | -2.0% | 0.25% | +32.6% |
| Q2 2017 | $1,422,000 | -17.3% | 51,000 | +2.0% | 0.19% | -16.5% |
| Q1 2017 | $1,719,000 | +19.2% | 50,000 | 0.0% | 0.22% | +23.1% |
| Q4 2016 | $1,442,000 | -9.4% | 50,000 | 0.0% | 0.18% | -14.2% |
| Q3 2016 | $1,591,000 | -2.0% | 50,000 | 0.0% | 0.21% | +2.9% |
| Q2 2016 | $1,623,000 | +9.5% | 50,000 | -5.7% | 0.21% | +13.2% |
| Q1 2016 | $1,482,000 | -21.5% | 53,000 | 0.0% | 0.18% | -15.0% |
| Q4 2015 | $1,889,000 | – | 53,000 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |